All In Biotech

Drug Trial Radar · NCT06413680

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

A Phase 1/2a, Open-Label, Dose Escalation and Dose Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti-PD-1-IL-2RA-IL-2 Fusion Protein) Alone or in Combination With Cemiplimab in Patients With Advanced Solid Organ Malignancies

Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Sep 23, 2024

Primary completion

Feb 3, 2030

Study completion Feb 3, 2030

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
May 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and effective the study drug(s) are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug(s) * How much study drug(s) is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)

Conditions

  • Melanoma
  • Clear-Cell Renal-Cell Carcinoma (ccRCC)
  • Advanced Solid Tumors

Interventions

  • REGN10597Drug

    Administered per the protocol

  • CemiplimabDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose-Limiting Toxicities (DLTs)Time frame: Up to Day 29
  2. Incidence of Treatment-Emergent Adverse Event (TEAEs)Time frame: Approximately 6 Years
  3. Incidence of Serious Adverse Events (SAEs)Time frame: Approximately 6 Years
  4. Incidence of TEAEs leading to treatment discontinuationTime frame: Approximately 6 Years
  5. Incidence of TEAEs leading to deathTime frame: Approximately 6 Years
  6. Number of participants with Grade 3 laboratory abnormalitiesTime frame: Approximately 6 Years
  7. Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria by investigator assessmentTime frame: Approximately 6 Years

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • University of California San Francisco (UCSF)

    San Francisco, California · Recruiting

  • Yale School of Medicine

    North Haven, Connecticut · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • Start Midwest Cancer Research

    Grand Rapids, Michigan · Recruiting

  • Northwell Health

    Lake Success, New York · Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • University of Pittsburgh Medical Center - Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Next Oncology

    San Antonio, Texas · Recruiting

  • The Start Center for Cancer Care

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.